Mechanism of Action and Receptor Profile
The primary mechanism of this drug class involves the direct stimulation of dopamine receptors located in the neostriatum.
These drugs possess a specific receptor profile, typically exhibiting the highest pharmacological activity toward D2 receptors.
Classification includes non-selective agonists that act simultaneously on D1 and D2 receptors. This category includes pergolide, bromocriptine, and pramipexole. Notably, pramipexole has a unique feature: in addition to D2 receptors, it additionally stimulates D3 receptors.
Chemically, some representatives (pergolide and bromocriptine) are ergot alkaloid derivatives.
Pharmacodynamics Using Bromocriptine as an Example
Bromocriptine (Bromocriptine) is a classic representative of direct dopamine receptor agonists (predominantly the D2 type). Structurally, it is a semi-synthetic ergot alkaloid derivative, specifically of ergocriptine.
Its action in the body is characterized by two key directions:
- Antiparkinsonian effect: achieved through active stimulation of D2 receptors localized in the neostriatum.
- Endocrine effect: the drug stimulates pituitary D2 receptors, leading to a marked decrease in prolactin release from the anterior pituitary gland.
Clinical Application and Administration Regimens
Dopamine receptor agonists possess a critically important pharmacokinetic advantage: their duration of action exceeds that of levodopa. This determines their role in treatment regimens.
- Bromocriptine and pergolide are primarily prescribed as part of combination therapy alongside levodopa. This combination is particularly relevant when levodopa clinical efficacy is insufficient or when the patient develops the specific "on-off" motor fluctuation syndrome.
- Pramipexole is considered more potent than bromocriptine, allowing it to be used successfully both in combination with levodopa and as monotherapy.
Side Effects and Management Strategies
Therapy with direct agonists can be accompanied by adverse reactions, which are generally divided into early-onset and long-term effects.
Early-Onset Effects:
- Orthostatic hypotension.
- Dyspeptic symptoms (nausea and vomiting). The mechanism of nausea involves the stimulation of D2 receptors in the chemoreceptor trigger zone of the vomiting center. To correct this, domperidone—a peripheral dopamine receptor antagonist that does not cross the blood-brain barrier—is administered.
Specific Reactions to Pramipexole:
- Excessive daytime somnolence.
- Sudden sleep attacks.
Long-Term Effects:
- Psychiatric disturbances, including hallucinations and psychosis.
- Motor abnormalities presenting as dyskinesias.
Differences from Other Antiparkinsonian Drugs
Within the classification of antiparkinsonian agents, direct agonists must be clearly distinguished from other drug classes:
- Levodopa is a metabolic precursor of dopamine, not a direct agonist.
- Carbidopa is an aromatic L-amino acid decarboxylase (DOPA decarboxylase) inhibitor used strictly in combination with levodopa.
- Selegiline acts as an MAO-B inhibitor, preventing the enzymatic degradation of dopamine.
- Trihexyphenidyl (benzhexol) belongs to the central antimuscarinic (anticholinergic) drug class.